Anti-PD1 checkpoint inhibitor therapy in acral melanoma: a multicenter study of 193 Japanese patientsYasuhiro Nakamura, N. Yamazaki, Haruki Doi et al.|Annals of Oncology|2020Cited by 140
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patientsKaori Sakaizawa, Hisashi Uhara, Tatsuya Takenouchi et al.|Journal of Dermatological Science|2015Cited by 120
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanomaYasuhiro Fujisawa, Norito Katoh, Jun Asai et al.|Cancer Medicine|2019Cited by 111
Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging systemYasuhiro Fujisawa, Norito Katoh, Jun Asai et al.|Journal of Dermatological Science|2019Cited by 26
Systemic therapy for Asian patients with advanced <scp>BRAF V600</scp>‐mutant melanoma in a real‐world setting: A multi‐center retrospective study in Japan (<scp>B‐CHECK‐RWD</scp> study)Kenjiro Namikawa, Naoya Yamazaki, Jun Asai et al.|Cancer Medicine|2023Cited by 25